Dr Aftab Khan, consultant cardiologist at Apollo Multispeciality Hospitals, Kolkata, tells Umesh Isalkar which patients should consider these drugs first, and why they can complement but not replace proven therapies and lifestyle changes.Why are cardiologists now calling GLP-1 receptor agonists like semaglutide and tirzepatide heart medicines
Regulatory peptides , 160 (1-3), 2632
Preliminary data from the JSKN016-101 trial reveal a distinct safety profile: the most frequent treatment-related adverse events (TRAEs) were nausea, vomiting, and oral mucositis
Ali noted that people with obesity should view it as a chronic, long-term disease similar to hypertension or diabetes. Those using GLP-1 medications should approach them as a long-term treatment plan, Ali said
Asetil l karnitin ne ie yarar derseniz
doi: 10.1186/s13287-022-03147-w